Regimens combining radiation and immunotherapy for cancer: latest updates from 2024 ASCO Annual Meeting
Combination of immunotherapy with radiotherapy is under active investigation. The PACIFIC trial firmly established the treatment paradigm of consolidation immunotherapy following definitive chemoradiotherapy, inspiring a series of similar or exploratory combination regimens. This summary highlighted six reports updated in the 2024 ASCO Annual Meeting.
Authors
- Leilei Wu
- Shengxiang Ren (ORCID: https://orcid.org/0000-0001-8767-9850)
- Xiaoling Xu (ORCID: https://orcid.org/0000-0002-0852-0225)
- Ming Liu (ORCID: https://orcid.org/0000-0002-6617-4025)
- Min Hu (ORCID: https://orcid.org/0000-0002-0121-6458)
- Yaping Xu (ORCID: https://orcid.org/0009-0002-9109-1958)
- Shuangyan Yang (ORCID: https://orcid.org/0000-0001-9667-7814)
- Di Liu (ORCID: https://orcid.org/0009-0008-1512-5662)
Institutions
- Tongji University (CN)
- Shanghai Pulmonary Hospital (CN)
Publication Details
- Journal
- Journal of Hematology & Oncology
- Published
- 2024-09-13
- DOI
- https://doi.org/10.1186/s13045-024-01587-w
- Citations
- 6
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.70
Funders
- Science and Technology Commission of Shanghai Municipality
- Shanghai Pulmonary Hospital